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Objectives. The goal of this study was to evaluate the effect of 
amiodarone on mortality, ventricular arrhythmias and clinical 
complications in high risk postinfarction patients. 
Background. No therapy has been shown to reduce sudden 
death in patients ineligible to receive beta-adrenergic blocking 
agents after myocardial infarction. 
Methods. Patients who were not eligible to receive beta-
blockers were randomized to receive amiodarone (n = 305) or 
placebo (n = 308) for 1 year. 
Results. There were 21 deaths in the amiodarone group 
compared with 33 in the placebo group (odds ratio 0.62, 95% 
confidence interval [CI] 0.35 to 1.08, p = 0.(95). There were two 
noncardiac deaths in the amiodarone group and none in the 
placebo group; thus, the difference in cardiac mortality (19 vs. 33, 
Approximately 10% of patients discharged from the hospital 
after acute myocardial infarction die in the 1st year (1-3). 
Beta-adrenergic blocking agents have been demonstrated 
(4-6) to reduce the risk of death during this period by about 
25%. Unfortunately, a large number of patients after an 
acute myocardial infarction have contraindications to beta-
blockers (4-6), and only about 25% to 50% discharged after 
an acute infarction are eligible to receive these agents (4,6). 
Patients who are considered to have contraindications to the 
use of beta-blockers after infarction often have a poor 
prognosis because of a relatively high incidence of heart 
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respectively) was statistically significant (odds ratio 0.55, 95% CI 
0.32 to 0.99, P = 0.048). There was a significant decrease in Lown 
class 4 ventricular arrhythmias (7.5% vs. 19.7%, respectively, p 
< 0.001). Adverse effects developed in 30% of amiodarone-treated 
patients and 10% of placebo-treated patients. Pulmonary toxicity, 
which was mild and reversible, occurred in only one patient in the 
amiodarone group but in no patient in the placebo group. 
Conclusions. This trial demonstrated a significant reduction in 
cardiac mortality and ventricular arrhythmias with amiodarone 
treatment. However, given the wide confidence intervals and 
borderline statistical significance of our trial, larger trials are 
needed to confirm or refute this view. 
(J Am CoU CardioI1992j20:1056-62) 
failure, diabetes, bronchial asthma or symptomatic periph-
eral arteriosclerosis. 
Recently angiotensin-converting enzyme inhibitors have 
been shown to improve survival in patients with a low 
ejection fraction after myocardial infarction or with concom-
itant heart failure (7-9). However, the overall reductions in 
mortality in these trials were modest and there was little 
effect on deaths that were presumed to be arrhythmic. A 
significant proportion of the increased risk of death during 
the 1st year after infarction is due to serious arrhythmias. 
Class I antiarrhythmic agents have not been demonstrated to 
reduce mortality (10) and some of these agents (for example, 
encainide and fiecainide) have been shown (11) to increase 
the risk of death despite suppression of arrhythmias. In this 
study, we selected amiodarone because it has been reported 
to be a relatively safe and effective antiarrhythmic agent in 
low doses (12-21) and is one of the few such agents that is 
well tolerated by patients with heart failure. In addition to 
antiarrhythmic properties, it has anti sympathetic (22,23) and 
antithyroid (24,25) properties that are likely to further de-
crease electrical instability of the cardiac muscle. Amio-
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darone exerts negligible or minimal proarrhythmic effect 
(26-31). The most serious side effect is pulmonary toxicity, 
with a reported frequency as high as about 6% (32). The risk 
of pulmonary toxicity increases with high doses and the 
majority of patients with this complication have received 
amiodarone maintenance doses >400 to 600 mg/day (33). 
The aim of this feasibility study was to investigate 
whether low doses of amiodarone could be used safely in 
patients who survived the early phase of myocardial infarc-
tion and who were considered unsuitable to receive beta-
blockers because of contraindications. In addition, we as-
sessed the impact of amiodarone on total and cardiac 
mortality, serious arrhythmias and tolerance of the drug 
during low dose therapy. 
Methods 
Study patients. The study was conducted in eight medical 
school hospitals in Warsaw, Krakow, Lodz and Bydgoszcz, 
Poland, serving approximately 2.5 million persons. Recruit-
ment began in January 1986 and was completed by Decem-
ber 31, 1989. Patient eligibility was assessed between the 5th 
and the 7th day after hospital admission. 
Patients were eligible if they met the following criteria: 
1) age <75 years; 2) residence in the catchment areas; 3) a 
confirmed diagnosis of acute myocardial infarction based on 
the presence of at least two of the following three criteria: a 
typical history of retrosternal pain lasting >30 min; typical 
electrocardiographic (ECG) alterations; raised serum en-
zyme levels of aspartate amino transferase (AST) and creat-
ine kinase, MB fraction greater than twice the upper limit of 
the normal range at each hospital laboratory. 
Table 1 lists the reasons for exclusion from the study. Of 
4,212 patients who fulfilled the entry criteria and were 
evaluated for the study, 3,599 patients were excluded. The 
main reasons for exclusion were cardiovascular conditions, 
lack of contraindications to beta-blockers, atrial fibrillation 
and need for an antiarrhythmic agent. Beta-blockers were 
considered contraindicated if patients had heart failure, 
bronchial asthma, treated diabetes or peripheral artery dis-
ease with claudication. 
The protocol was approved by the Ethical Committee of 
the Ministry of Health, Warsaw. After informed consent was 
obtained, patients were randomized between the 5th and 7th 
days after admission, separately in each center according to 
random numbers in sealed envelopes prepared by the inde-
pendent statistical unit. 
Experimental regimen. Six hundred thirteen patients 
were randomly allocated to treatment in double-blind fash-
ion, 308 received placebo and 305 amiodarone. Amiodarone 
or placebo was given at an initial dose of 800 mg/day for the 
first 7 days. Thereafter 400 mg was administered 6 days a 
week for 12 months. This dose could be reduced to 
200 mg/day and even to 100 mg/day if heart rate decreased to 
<55 beats/min or if the QT interval was >0.48 s. All patients 
were in sinus rhythm at entry into the study. Patients who 
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Table 1. Reasons for Patient Exclusion Before Randomization 
Total patients I'oith confirmed acute myocardial infarction 6,249 
Age ~75 years 1,329 
Not living in the catchment areas 167 
Death <5 days of admission 541 
Patients fulfilling the entry criteria (total) 4,212 
Patients excluded from the trial (total) 3,599 
Reasons for exclusion: 
Cardiovascular causes 1,320 
Hypotension «100 mm Hg) 161 
Bradycardia «60 beats/min) 239 
A v block W to IW) 393 
Bundle branch block 482 
QTc ~0.5 s 40 
Other cardiovascular causes 5 
Candidate for beta-blocker therapy 1,441 
Need for antiarrhythmic agents 559 
Serious noncoronary disease 84 
Amiodarone given in the past 6 months 76 
Omitted in error 8 
Refusal to participate III 
Patients included in the trial 6/3 
A V = atrioventricular; I" to III" = first-degree to third-degree; QTc = 
corrected QT interval. 
developed serious arrhythmias (Lown grade 4) during the 
follow-up period could receive an antiarrhythmic class IB 
agent without breaking the study code. If this medication 
was effective, the patient continued the trial regimen. If the 
arrhythmia was not suppressed, treatment with placebo or 
amiodarone was stopped and the patient was treated at the 
discretion of the attending physician. 
The trial regimen was stopped if the patient developed a 
decrease in heart rate to <50 beats/min, any type of heart 
block, a QT interval >0.5 s, a new myocardial infarction or 
significant new pulmonary symptoms. 
Under the protocol, the occurrence of corneal deposits or 
skin changes attributed to amiodarone would lead to discon-
tinuation of the study medication only if the patient or the 
attending physician considered them to be intolerable or 
severe. 
Follow-up observations. All patients returned for fol-
low-up examinations performed by a cardiologist at weeks 1, 
2,3,6,8, 10, 12, 14, 18,22,26,30,34,46 and 52. At the end 
of the 12 months offollow-up in each patient, the code was 
broken and the information provided to the patient's physi-
cian who was responsible for further management. 
Variables recorded. Twenty-four hour Holter ambulatory 
ECG recordings were obtained at week 2, at 6 months and at 
1 year. Two-dimensional echocardiograms were performed 
on the day of randomization and at 2 and 26 weeks. Ejection 
fraction was calculated according to Simpson's method (34). 
Chest X-ray examination was performed in weeks 2, 12,24 
and 52, triiodothyronine and thyroxine were analyzed by a 
radioimmunoassay (35). Routine laboratory tests were con-
ducted on the day of randomization and at weeks 6, 14,26, 
40 and 52. Slit lamp ophthalmologic examinations were 
conducted at weeks 2, 10, 22 and 40. 
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Compliance. The patients's compliance with treatment 
was judged primarily by tablet counts at every visit. Assays 
of amiodarone and desethylamiodarone in blood were per-
formed with high performance liquid chromatography (36) in 
186 patients randomly chosen (90 receiving amiodarone and 
96 placebo) after 6 and 40 weeks in the trial. To maintain 
blinding, this information was not shared with the individual 
investigators. 
End.point evaluation. Vital status was ascertained in all 
patients at the end of the study. The main end-points of the 
study were cardiac mortality and death from any cause. 
Independent consultants who were unaware of treatment 
allocation verified classification of each event. All patients 
who were randomized were included in the analysis whether 
or not the allocated regimen had been discontinued. Fol-
low-up for clinical events was 100% complete. The prospec-
tively defined secondary end-point was the occurrence of 
serious ventricular arrhythmias (Lown grade 4) detected by 
24-h Holter recordings or on the standard ECG at the 
prespecified visits. 
Statistical methods. No formal sample size was calcu-
lated for this pilot phase, which was designed primarily to 
assess feasibility and safety. Funds were available for 4 
years of recruitment and a further I-year follow-up of the last 
patient. Because we did not expect to observe striking 
differences in mortality, the entire pilot study was planned to 
be completed. Therefore no adjustments in the reported p 
value have been made. Baseline characteristics of two 
groups were compared using the chi-square test for discrete 
variables. The mortality curves in the two groups were 
compared by using the log rank statistic (37). All p values 
quoted are two-tailed. Unless otherwise indicated, values 
are expressed as mean value ± 1 SD. 
Results 
Comparison of baseline characteristics of the treatment 
groups. Of the 613 patients who were randomly assigned, 
305 received amiodarone and 308 received placebo. Table 2 
compares selected baseline clinical and laborat9ry variables 
in the two groups; there were no significant differences 
between groups in any baseline variable. 
Mortality. There were 33 deaths (10.7%) in the placebo 
group versus 21 (6.9%) in the amiodarone group (odds ratio 
0.62, 95% confidence intervals [CI] 0.35 to 1.08, p = 0.095). 
In the amiodarone group, one patient died of stomach cancer 
and one of a stroke. All 33 deaths in the placebo group were 
due to cardiac causes compared with 19 (6.2%) of 21 in the 
amiodarone group (odds ratio 0.55,95% CI 0.32 to 0.99). The 
difference in cardiac death between the two groups is statis-
tically significant (p = 0.048) and suggests that treatment is 
indeed beneficial. Nine cardiac deaths in the amiodarone 
group occurred during therapy and 10 occurred after cessa-
tion of therapy but within the predefined 12-month follow-up 
period. 
Figure 1 shows the cumulative number of cardiac deaths 
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(n = 305) (n = 308) 
Age (yr) (mean ± SD) 59.4 ± 12.3 58.6 ± 11.8 
Female 88 (28.9) 98 (31.8) 
Male 217 (71.1) 210 (68.2) 
Medical history 
Treated hypertension 132 (43.3) 148 (48.1) 
Treated diabetes 60 (19.7) 58 (18.8) 
Documented previous MI 50 (16.4) 45 (14.6) 
First day of qualifying infarct 
Arrhythmia grade 
Lown 4a 20 (6.6) 17 (5.5) 
Lown4b 27 (8.9) 24 (7.8) 
Lown5 7 (2.3) 11 (3.6) 
Medications 
Digoxin 36 (11.8) 46 (14.9) 
Diuretics 106 (34.8) 112 (36.4) 
Nitrates IV III (36.4) 111 (36.0) 
Site of qualifying infarct 
Anterior 156 (51.1) 157 (51.0) 
Inferior 138 (45.2) 136 (44.2) 
Other location 11 (3.6) 15 (4.9) 
Ejection fraction (on the day n = 252 n = 260 
of randomization) 
~40% 154 (61.1) 155 (59.6) 
<40% 98 (38.9) 105 (40.4) 
Unless otherwise indicated, data are presented as number (%) of patients. 
IV = intravenously; MI = myocardial infarction. 
in all patients randomly allocated to treatment with amio-
darone and placebo during the trial. Most of the deaths in 
both groups occurred within the 1st 6 months of the trial, and 
there was no difference between groups in mortality at 4 
weeks. 
Sudden death was defined as death occurring within 1 h of 
the onset of symptoms or unwitnessed death. There were 10 
Figure 1. Survival curves of patients who did not die of cardiac 
causes and were randomly allocated to treatment with amiodarone 
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Figure 2. Patients receiving amiodarone or placebo who had Lown 
grade 4 arrhythmias detected by Holter ambulatory electrocardio-
graphic monitoring (at 2 weeks, between 4 and 18 weeks, between 22 
and 26 weeks, between 46 and 52 weeks and at any time). 
sudden deaths (3.3%) in the amiodarone group and 20 (6.5%) 
in the placebo group (p = 0.07). 
Ventricular arrhythmias (Fig. 2). The incidence of seri-
ous ventricular arrhythmias (Lown grade 4) was significantly 
lower in the amiodarone group (7.5%) than in the placebo 
group (19.5%) (p < 0.001). These arrhythmias occurred 
mainly within the 1st 6 months of the trial. When serious 
arrhythmias were detected, patients were readmitted to the 
hospital and given a class IB antiarrhythmic agent according 
to the protocol. This procedure was not effective in 7 
patients (30.4%) receiving amiodarone and in 18 patients 
(30%) receiving placebo. In these patients, treatment with 
the study drug was stopped. 
Adverse reactions and withdrawal (Tables 3 and 4). Ad-
verse reactions that were considered to be related to the 
study medication occurred in 30.1% of patients randomized 
to receive amiodarone as opposed to 10.3% of patients 
randomized to placebo. Bradycardia, first-degree atrioven-
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Table3. Adverse Reactions Considered to Be Due to Amiodarone 
Amiodarone Group Placebo Group 
(n = 305) (n = 308) 
Patients with reactions 
No. 92 [55) 32 (19) 
% 30.2 (18) 10.3 [6.2) 
Bradycardia 49 (14) 17 (4) 
Tachycardia 0 3 (3) 
AV block 12 (12) 6 (6) 
First degree 11 [11) 6 (6) 
Second degree I (1) 0 
Sinus pause 
<3 s 2 [2] 0 
>3 S 0 0 
Right bundle branch block I [I] I [1] 
Left bundle branch block 5 [5] I [1] 
Prolongation of QT interval 5 [5] 0 
Low cardiac output I [1] 0 
Hyperthyroidism II [11] I [1] 
Severe corneal microdeposits 9 [7] 0 
Gastrointestinal 0 2 [2] 
Pulmonary toxicity" I [I] 0 
Blue-skin I [1] I [1] 
'Symptoms resolved after administration of corticosteroids. Unless oth-
erwise noted, numbers indicate number of patients; numbers in brackets 
indicate patients withdrawn from the study. Some patients showed more than 
one symptom. AV = atrioventricular. 
tricular (A V) block and hyperthyroidism were the most 
common reactions (Table 3). 
Although hyperthyroidism was the reason for withdrawal 
from the study in II patients, clinical symptoms of hyper-
thyroidism and elevated triiodothyronine were found in only 
three patients. The remaining eight patients were excluded 
solely on the basis of increased thyroxine. Minor corneal 
deposits occurred in the vast majority of patients receiving 
amiodarone. No patient complained of visual symptoms. 
A number of patients were withdrawn for various reasons 
believed not to be related to study medication (Table 4). 
Compliance. Tablet counts in the returned bottles 
showed that the mean tablet consumption was 96% of that 
prescribed. Amiodarone blood levels in the active group was 
0.87 ± 0.52 ng/ml and that of desethylamiodarone was 0.5 ± 
Table 4. Number of Patients Withdrawn for Reasons Other Than 
Side Effects 
Amiodarone Group Placebo Group 
Reasons for Withdrawal (n = 305) (n = 308) 
Definite reinfarction 14 10 
Possible reinfarction 0 2 
Lown grade 4 arrhythmias' 7 20 
Stroke 2 2 
Hepatitis B 2 2 
Withdrawn in error I 
Noncompliance 23 23 
Total 48 60 
"Not controlled with class IB drugs. 
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0.28 ng/mt. No patient receiving placebo had detectable 
amiodarone levels in their blood. 
Reduction of the dose of study medication. The daily dose 
of amiodarone was reduced in 96 patients: from 400 to 
200 mg in 86 patients (30.5%) and to 100 mg in 10 (3.3%). The 
main reasons for reducing the dose were lengthening of the 
QT interval (49%) and bradycardia (25%). The daily dose of 
placebo was reduced to 200 mg in 32 patients (10.4%). The 
mean daily dose of amiodarone was 326 ± 112 mg in all 305 
patients randomized to amiodarone. It was only 278 + 
105 mg in the 193 patients who took amiodarone throughout 
the trial because of the reduction in dose in 96 of these 
patients during the course of the study. In patients who 
stopped taking the medication during the trial, the drug was 
given at a mean daily dose of 423 ± 118 mg. This latter group 
includes 10 patients in whom the dose was reduced. 
Overall, 103 patients receiving amiodarone and 79 receiv-
ing placebo stopped taking the study drug by the end of 1 
year (Tables 3 and 4). In the amiodarone group, administra-
tion of the drug was stopped because of adverse effects in 55 
patients and for other reasons in 48; in the placebo group it 
was stopped for these causes in 19 and 60 patients, respec-
tively. 
Discussion 
This study suggests that amiodarone reduced cardiac 
mortality among patients at high risk after acute myocardial 
infarction who were not suitable for secondary prevention \ 
with beta-blockers because of contraindications. This benefit 
was achieved with relatively few major side effects. This trial 
was designed as a feasibility project to conduct a future 
larger study with greater statistical power to detect differ-
ences in mortality. We were therefore surprised to observe a 
38% reduction in odds of total mortality and a 44% reduction 
in odds of cardiac mortality. 
The reduction in mortality was entirely due to a reduction 
in cardiac mortality (p = 0.05), which in turn was due chiefly 
to a reduction in sudden death (10 vs. 20). Our results on 
mortality should be cautiously interpreted given the small 
size of the study, the borderline statistical significance and 
the very wide confidence intervals for both total mortality 
(odds ratio 0.35 to 1.08) and cardiac mortality (odds ratio 
0.32 to 0.99). Nevertheless, our favorable results are consis-
tent with the results of Burkart et at. (38), who observed a 
significant reduction in mortality (5 deaths among 98 patients 
in the amiodarone group vs. 15 deaths among 115 patients in 
the control group, p < 0.05). Other small studies also 
demonstrated a favorable trend. Overall, the combined data 
from five trials on a total of 1,150 patients indicate a 29% 
reduction in mortality (95% CI 52% reduction to 3% in-
crease, p = 0.07) (10). At present, this overall estimate is 
probably the best indicator of the potential benefit of amio-
darone. However, given the wide confidence intervals, there 
is considerable uncertainty about the magnitude of effect. 
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Several ongoing trials that are expected to randomize a total 
of about 3,000 patients should further clarify the impact of 
this therapy on mortality. 
Our study demonstrated a significant reduction in serious 
ventricular arrhythmias (Lown grade 4) in the amiodarone 
group. However, we had not anticipated that the incidence 
of asymptomatic Lown grade 4 arrhythmias would be as high 
as 20% in patients receiving routine treatment (placebo 
group) after acute myocardial infarction. This result may be 
due to the inclusion of high risk patients in our trial and the 
frequency of Holter ambulatory ECG monitoring. In the 
amiodarone group, the incidence of such arrhythmias was 
reduced to 7.5% (p < 0.(01). 
Our protocol differed from those of several previous 
studies of antiarrhythmic therapies in important ways. 1) 
Several previous studies (10,11) on antiarrhythmic agents in 
secondary prevention included only those patients who 
displayed frequent ventricular arrhythmias. However, we 
decided to include all patients who were eligible after myo-
cardial infarction irrespective of the frequency of ventricular 
arrhythmias, because most high risk patients have myocar-
dial damage that is sufficient to act as a substrate for 
arrhythmias. 2) The predictive power of 24-h Holter ambu-
latory ECG monitoring to identify patients who are likely to 
die is only moderate (39). 3) Bursts of very serious ventric-
ular arrhythmias that lead to cardiac arrest might occur in 
patients who may have no arrhythmias on the baseline 
Holter ECG. In our protocol, we did not attempt to titrate 
therapy to achieve arrhythmia suppression in every patient. 
Although we observed a clear reduction in arrhythmias with 
treatment, it may well be that the antifibrillatory properties 
of amiodarone, rather than its ability to suppress asympto-
matic arrhythmias, are responsible for the observed benefit. 
Amiodarone, with its mUltiple beneficial mechanisms of 
action in addition to its direct e1ectrophysiologic properties, 
seemed to be well suited for such an approach. A similar 
rationale and approach were utilized by Hamer et at. (15), 
who reported a beneficial effect of amiodarone in patients 
with congestive heart failure. 
Possible side effects of the study medication occurred in 
92 patients (30.2%) allocated to receive amiodarone. Of 
these, 55 (18%) had to be withdrawn from treatment, a rate 
similar to those reported in other studies (12-20) utilizing 
similar maintenance doses. The vast majority of withdrawals 
in the amiodarone group were due to first-degree A V block, 
hyperthyroidism, bradycardia and corneal microdeposits. 
Although we withdrew medication in the 11 patients who 
developed first-degree A V block, it is unclear whether this 
step was necessary to maintain patient safety. On the basis 
of our current experience, we would stop medication only if 
high grade A V block developed. Hyperthyroidism was the 
reason for withdrawal of medication in 11 patients. Of these, 
three patients displayed clinical symptoms and a rise in 
triiodothyronine levels. The remaining eight patients were 
withdrawn solely because of an increase in thyroxine, which 
in isolation is not necessarily a marker of hyperthyroidism in 
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patients receiving amiodarone. Amiodarone decreases the 
peripheral conversion of thyroxine to triiodothyronine, caus-
ing an increase in thyroxine (24). The number of patients 
withdrawn from the study because of bradycardia would 
have been less had the protocol been more strictly observed. 
Six patients from the amiodarone group and two from the 
placebo group were withdrawn, although their heart rates 
did not reach the criterion for withdrawal (50 beats/min). It is 
therefore possible that true amiodarone-induced side effects 
were the real reason for withdrawal in approximately 30 to 
35 patients (about 10%). Conversely, it is also possible that 
a longer duration of amiodarone therapy leads to higher 
tissue concentrations of the drug and increases the potential 
for adverse effects. 
The adverse reactions encountered were not serious and 
resolved spontaneously in all patients after treatment was 
stopped. Pulmonary toxicity due to amiodarone can occa-
sionally be severe and life-threatening. We observed this 
condition in only one patient. The clinical symptoms were 
mild and the diagnosis was based on a routine chest X-ray 
examination that was performed according to the protocol. 
All symptoms in this patient subsided after the use of 
corticosteroids. Larger studies with longer follow-up may be 
needed to obtain a precise estimate of the incidence of 
arniodarone-induced pUlmonary toxicity, especially after 1 
year. However, our data indicate that the absolute risk of 
developing this complication is likely to be low if the drug is 
used for <1 year. 
Conclusions. Although this study was designed to be a 
feasibility trial, it nevertheless suggests that amiodarone 
reduces cardiac mortality among patients at high risk after 
acute myocardial infarction, who have contraindications to 
beta-blocker therapy. A clear reduction in serious arrhyth-
mias was also seen. The protocol adopted in our trial proved 
to be safe, and side effects were minimal during 1 year of 
therapy. Larger studies of perhaps longer duration are 
justified to confirm or refute our promising findings. 
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